Heterobicyclic compounds

US9174992B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Jennifer R. Allen · Newbury Park, US
• Albert Amegadzie · Moorpark, US
• Kristin L. Andrews · Thousand Oaks, US
• James Brown · Moorpark, US
• Jian Chen · Camarillo, US
• Ning Chen · Thousand Oaks, US
• Essa Hu Harrington · Camarillo, US
• Qingyian Liu · Camarillo, US
• Thomas Nguyen · Newbury Park, US
• Alexander J. Pickrell · Westlake Village, US
• Wenyuan Qian · Newbury Park, US
• Shannon Rumfelt · Camarillo, US
• Robert M. Rzasa · Ventura, US
• Chester Chenguang Yuan · Newbury Park, US
• Wenge Zhong · Thousand Oaks, US

Key dates

• Filing date: Feb 28, 2013
• Grant date: Nov 3, 2015
• Expiry date: May 11, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Heterobicyclic compounds of Formula (I):or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.